Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers
Conditions
Interventions
PF-04878691 3mg
PF-04878691 6mg
+1 more
Locations
1
United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Start Date
January 1, 2009
Primary Completion Date
November 1, 2009
Completion Date
November 1, 2009
Last Updated
December 1, 2009
NCT05361603
NCT06868264
NCT07388979
NCT05975216
NCT05071261
NCT00894257
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions